Onco-Summaries: Daily Oncology Updates at a Glance

07/08/2026

---

• BioInvent Secures US FDA Fast Track Designation for BI‑1808 in Ovarian Cancer

---

BioInvent Secures US FDA Fast Track Designation for BI‑1808 in Ovarian Cancer (Ref)

BioInvent has received US FDA Fast Track designation for BI‑1808, its first‑in‑class anti‑TNFR2 antibody, in combination with pembrolizumab for the treatment of ovarian cancer

Supporting Phase 2a study results:

• 24.0% confirmed overall response rate (ORR)

• 56.0% disease control rate (DCR)

• Median progression‑free survival (mPFS): 10.3 mos

• Durable responses, some ongoing beyond 10.0 mos

Return to Top